“没什么大不了的”：一项定性研究，探讨药师对米非司酮药物流产处方的看法。
"No Big Deal": A Qualitative Study of Pharmacists' Perspectives on Dispensing Mifepristone for Medication Abortion.
机构信息
Advancing New Standards in Reproductive Health (ANISRH), University of California, San Francisco, Oakland, California.
Department of Obstetrics and Gynecology, Oakland Medical Center, Kaiser Permanente Northern California, Oakland, California.
出版信息
Womens Health Issues. 2022 Nov-Dec;32(6):571-577. doi: 10.1016/j.whi.2022.06.007. Epub 2022 Jul 30.
INTRODUCTION
Until December 2021, the United States Food and Drug Administration impeded abortion access by restricting pharmacists from dispensing mifepristone, one of two drugs used in medication abortion. This study aimed to explore pharmacists' perspectives on dispensing mifepristone.
METHODS
We conducted semistructured interviews with pharmacists before and after participating in a pilot project where mifepristone was dispensed from their pharmacies. We thematically coded all interview transcripts, then summarized emergent themes related to pharmacists' support, comfort, experiences, and concerns around dispensing mifepristone.
RESULTS
Between May 2018 and July 2020, we interviewed 29 pharmacists (22 at baseline and 15 at follow-up, with 8 completing both interviews) from 5 pharmacies. At both baseline and follow-up, interviewees strongly supported pharmacists dispensing mifepristone, feeling it would improve quality of care by providing more convenient medication abortion access and streamlined service delivery and take advantage of pharmacists' expertise and availability. All pharmacists interviewed at follow-up reported dispensing mifepristone except two who were willing but did not have the opportunity. Pharmacists experienced few challenges dispensing mifepristone. Their main concern was perceived discomfort that other pharmacists and pharmacy staff may experience, particularly in conservative areas or small pharmacies where pharmacists' refusal to dispense mifepristone could impede abortion access.
CONCLUSIONS
Most pharmacists supported dispensing mifepristone and were comfortable doing so after education on mifepristone and medication abortion. They dispensed mifepristone without difficulty, in a similar process as dispensing other medications. With the recent removal of U.S. Food and Drug Administration restrictions prohibiting it, our findings support the feasibility of pharmacists dispensing mifepristone.
简介
截至 2021 年 12 月，美国食品和药物管理局（FDA）通过限制药剂师配发米非司酮（药物流产中使用的两种药物之一）来限制堕胎的获取途径。本研究旨在探讨药剂师配发米非司酮的观点。
方法
在参与一项试点项目前后，我们对药剂师进行了半结构化访谈，该试点项目允许从他们的药房配发米非司酮。我们对所有访谈记录进行了主题编码，然后总结了与药剂师在配发米非司酮方面的支持、舒适感、经验和关注点相关的新兴主题。
结果
在 2018 年 5 月至 2020 年 7 月期间，我们采访了来自 5 家药店的 29 名药剂师（基线时 22 名，随访时 15 名，其中 8 名完成了两次访谈）。在基线和随访时，受访者都强烈支持药剂师配发米非司酮，认为这将通过提供更方便的药物流产途径和简化服务提供来改善护理质量，并利用药剂师的专业知识和可用性。所有在随访时接受采访的药剂师都报告配发了米非司酮，只有两名药剂师愿意但没有机会。药剂师在配发米非司酮方面遇到的挑战很少。他们主要关注的是其他药剂师和药房工作人员可能会感到不适，特别是在保守地区或小药店，药剂师拒绝配发米非司酮可能会阻碍堕胎的获取。
结论
大多数药剂师支持配发米非司酮，并在接受米非司酮和药物流产方面的教育后对此感到舒适。他们在配发米非司酮时没有遇到困难，过程与配发其他药物相似。随着美国 FDA 最近取消了禁止配发米非司酮的规定，我们的研究结果支持药剂师配发米非司酮的可行性。
Zotero 插件